Published in Angewandte Chemie International Edition · View the paper (DOI)
Researchers have developed a new antibiotic, EZ120, that targets the mycomembrane biosynthesis of tuberculosis pathogen Mycobacterium tuberculosis. By inhibiting key enzymes, EZ120 significantly increases the effectiveness of conventional antibiotics, offering a novel approach for tuberculosis treatment.
Coverage from 2 institutions